- Dec 29, 2020
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
- Dec 28, 2019
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
- Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
- Dec 14, 2019
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
- Dec 7, 2019
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma
- Dec 6, 2018
NCT03582033: Phase 1 - A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
- Dec 16, 2016
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
- Dec 9, 2016
NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
- Dec 18, 2015
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
- Dec 10, 2015
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
- Dec 9, 2010
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
- Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
- Dec 29, 2005
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant